Castle Biosciences, Inc. (NASDAQ:CSTL – Get Rating) has been assigned a consensus rating of “Buy” from the eight analysts that are covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy rating. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $57.38.
Several research analysts have recently weighed in on the stock. Scotiabank assumed coverage on shares of Castle Biosciences in a research note on Wednesday. They issued a “sector outperform” rating and a $54.00 target price for the company. Robert W. Baird decreased their target price on shares of Castle Biosciences from $48.00 to $41.00 and set an “outperform” rating for the company in a research note on Thursday, November 3rd.
Insider Activity at Castle Biosciences
In related news, insider Derek J. Maetzold sold 2,869 shares of the company’s stock in a transaction on Monday, November 21st. The shares were sold at an average price of $20.84, for a total value of $59,789.96. Following the sale, the insider now directly owns 289,520 shares of the company’s stock, valued at $6,033,596.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Castle Biosciences news, insider Derek J. Maetzold sold 3,483 shares of the stock in a transaction on Monday, October 24th. The shares were sold at an average price of $20.41, for a total transaction of $71,088.03. Following the sale, the insider now directly owns 296,572 shares of the company’s stock, valued at $6,053,034.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Derek J. Maetzold sold 2,869 shares of the stock in a transaction on Monday, November 21st. The stock was sold at an average price of $20.84, for a total transaction of $59,789.96. Following the sale, the insider now directly owns 289,520 shares in the company, valued at $6,033,596.80. The disclosure for this sale can be found here. Insiders have sold 26,115 shares of company stock valued at $591,914 over the last ninety days. Corporate insiders own 7.30% of the company’s stock.
Institutional Trading of Castle Biosciences
Castle Biosciences Trading Down 0.2 %
Shares of CSTL stock opened at $22.80 on Wednesday. The company has a market capitalization of $600.83 million, a PE ratio of -11.12 and a beta of 1.00. The firm has a fifty day simple moving average of $22.76 and a 200-day simple moving average of $25.25. Castle Biosciences has a twelve month low of $15.58 and a twelve month high of $48.40.
Castle Biosciences (NASDAQ:CSTL – Get Rating) last announced its earnings results on Wednesday, November 2nd. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.07). The firm had revenue of $37.01 million during the quarter, compared to analysts’ expectations of $34.36 million. Castle Biosciences had a negative net margin of 42.79% and a negative return on equity of 11.87%. Equities research analysts predict that Castle Biosciences will post -2.91 EPS for the current year.
Castle Biosciences Company Profile
Castle Biosciences, Inc, a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma.
- Get a free copy of the StockNews.com research report on Castle Biosciences (CSTL)
- MarketBeat: Week in Review 01/02-01/06
- Why is the CrowdStrike Stock Price Struggling?
- Four Undervalued Healthcare Stocks for 2023
- WWE Stock: Vince McMahon Wants Back In The Show
- NVIDIA Is Bottoming But Don’t Buy It Just Yet
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.